Condition
Chronic Myeloid Leukemia, BCR/ABL-Positive
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06409936Phase 2Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT05413915Phase 3Active Not Recruiting
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
NCT05439889RecruitingPrimary
Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
Showing all 3 trials